Drugs that contain Bazedoxifene Acetate; Estrogens, Conjugated
1. Duavee patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7138392 | WYETH PHARMS | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
Apr, 2017
(7 years ago) | |
| US5998402 | WYETH PHARMS | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
Apr, 2019
(5 years ago) | |
| US7683051 | WYETH PHARMS | Crystalline polymorph of bazedoxifene acetate |
Mar, 2027
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8815934 | WYETH PHARMS | 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations |
May, 2019
(4 years ago) | |
| US6479535 | WYETH PHARMS | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
May, 2024
(16 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 13, 2018 |
| New Product(NP) | Oct 03, 2016 |
NCE-1 date: 13 October, 2017
Market Authorisation Date: 03 October, 2013
Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause; Prevention of postmenopausal osteoporosis
Dosage: TABLET;ORAL
More Information on Dosage
DUAVEE family patents
